Treadwell Therapeutics is a clinical-stage oncology company developing first-in-class cancer treatments. Combining synthetic lethality and immuno-oncology, its multi-modal platform spans small molecules, biologics, and cell therapies. Key pipeline assets include Ocifisertib (a PLK4 inhibitor in Phase 2/3 trials for TP53-mutated AML and breast cancer), CFI-402411 (an HPK1-FLT3 dual inhibitor), and CFI-402257 (a TTK inhibitor for ER+ breast cancer).